Generation of a selectively cytotoxic fusion protein against p53 mutated cancers

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kousparou, Christina A ^a,b   Yiacoumi, Efthymia ^a   Deonarain, Mahendra P ^b   Epenetos, Agamemnon A ^a,b  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antennapedia; Cancer therapy; Cell penetrating; p21; Recombinant fusion protein; Trojan

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; HYBRID PROTEIN; OXALIPLATIN; PACLITAXEL; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTENNAPEDIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DROSOPHILA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ERADICATION THERAPY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC TRANSDUCTION; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CANCER; RABBIT; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTENNAPEDIA HOMEODOMAIN PROTEIN; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESCHERICHIA COLI; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RABBITS; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864515136     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-338     Document Type: Article

References (34)

1. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
2. Leonardo AD, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994, 2540-2551.
3. Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996, 213:138-149.
4. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704. 10.1038/366701a0, 8259214.
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816. 10.1016/0092-8674(93)90499-G, 8242751.
6. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371:534-537. 10.1038/371534a0, 7935768.
7. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414. 10.1038/nrc2657, 2722839, 19440234.
8. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 2005, 277:443-456. 10.1016/j.ydbio.2004.07.044, 15617686.
9. Templeton NS, Lasic DD. Gene Therapy: Therapeutic Mechanisms and Strategies 2000, Marcel Dekker, New York.
10. Nielsen LL, Maneval IDC. p53 tumour suppressor gene therapy for cancer. Cancer Gene Ther 1998, 5:52-63.
11. Blagosklonny MV, El-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anticancer drug. Int J Cancer 1996, 67:386-392. 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6, 8707413.
12. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002, 9:553-566. 10.1038/sj.cgt.7700472, 12082455.
13. Katayose D, Wersto R, Cowun KH, Seth P. Effects of a recombinant adenovirus expressing WAFI/CIPI on cell growth, cell cycle and apoptosis. Cell Growth Differ 1995, 6:1207-1212.
14. Prabhu NS, Blagosklonny MV, Zeng YX, Wu GS, Waldman T, El-Deiry WS. Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction. Clin Cancer Res 1996, 2:1221-1229.
15. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. Cellular immune response to adenoviral vector infected cells does not require de novoviral gene expression: Implications for gene therapy. Proc Natl Acad Sci USA 1998, 95:11377-11382. 10.1073/pnas.95.19.11377, 21650, 9736744.
16. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000, 1:91-99.
17. Walsh G. Biopharmaceutical benchmarks 2010. Nature Biotech. 2010, 28:917-924.
18. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160. 10.1038/nrd1632, 15688077.
19. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994, 269:10444-10450.
20. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998, 8:84-87.
21. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009, 61:953-964. 10.1016/j.addr.2009.06.001, 19538995.
22. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy S. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572. 10.1126/science.285.5433.1569, 10477521.
23. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol 2000, 10:290-295. 10.1016/S0962-8924(00)01771-2, 10856932.
24. Sawant R, Torchilin V. Intracellular transduction using cell-penetrating peptides. Mol Biosyst 2010, 6:628-640. 10.1039/b916297f, 20237640.
25. Bonfanti MS, Taverna M, Salmona M, D'Incalci M, Broggini M. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 1997, 57:1442.
26. Ball KLS, Lain R, Fahraeus CS, Lane DP. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxyterminal domain of p21WAF1. Curr Biol 1997, 7:71. 10.1016/S0960-9822(06)00029-7, 8999999.
27. Mutoh M, Lung FD, Long YQ, Roller PP, Sikorski RS, O'Connor PM. A p21(Waf1/Cip1) carboxylterminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res 1999, 59:3480-3488.
28. Chung HK, Cheon GJ, Choi CW, Kim MJ, Lee SJ, Lim SM. Comparison of cellular metabolic responses of (18)F-FDG according to the effect of beta-irradiation in p53 wild and deleted cell lines. Cancer Biother Radiopharm 2007, 22:636-643. 10.1089/cbr.2007.331, 17979566.
29. De Gramont A, Cervantes A, Andre T, . OPTIMOX study FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2004, 22:251s. OPTIMOX study.
30. Min-Hsiung P, Wei-Jen C, Shoei-Yu LS, Chi-Tang H, Jen-Kun L. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Carcinogenesis 2002, 23:1677-1684. 10.1093/carcin/23.10.1677, 12376477.
31. Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 1999, 99:2467-2498. 10.1021/cr980421n, 11749487.
32. Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol 2009, 20:708-714. 10.1016/j.copbio.2009.10.006, 19880308.
33. Cheng JD, Werness BA, Babb JS, Meropol NJ. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res 1999, 5:1057-1062.
34. Geller JI, Szekely-Szucs K, Petak I, Doyle B, Houghton JA. P21cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. Cancer Res 2004, 64:6296-6303. 10.1158/0008-5472.CAN-04-0863, 15342418.